Please login to the form below

Not currently logged in
Email:
Password:

Yondelis

This page shows the latest Yondelis news and features for those working in and with pharma, biotech and healthcare.

Lilly snags first approval for sarcoma drug Lartruvo

Lilly snags first approval for sarcoma drug Lartruvo

Another drug - Johnson &Johnson's Yondelis (trabectedin) - was approved in 2015 for two specific types of STS (liposarcoma and leiomyosarcoma).

Latest news

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    If approved, the drug will join other new therapies for STS, including Johnson &Johnson's chemotherapy agent Yondelis (trabectedin) and Eisai's Halaven (eribulin mesylate), both of which have been approved

  • NICE recommends two drugs for ovarian cancer but rejects three NICE recommends two drugs for ovarian cancer but rejects three

    But the cost-effectiveness body rejected GlaxoSmithKline's Hycamtin (topotecan), PharmaMar's Yondelis (trabectedin) and Lilly's Gemzar (gemcitabine) for treating the first recurrence of platinum-sensitive ovarian cancer.

  • Novartis curates interactive history of medicine exhibition Novartis curates interactive history of medicine exhibition

    Another firm active in this space is Pharma Mar, whose marine-derived antitumoral agent Yondelis (trabectedin) received US approval last month to treat unresectable or metastic liposarcoma or leiomyosarcoma. .

  • FDA approves Janssen’s Yondelis FDA approves Janssen’s Yondelis

    Janssen's Yondelis has been approved by the FDA for the treatment of unresectable or metastic liposarcoma or leiomyosarcoma. ... The US approval comes on the back of data from a phase III trial which evaluated Yondelis (trabectedin) versus dacarbazine.

  • PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma PharmaMar/J&J’s Yondelis fast-tracked by FDA for sarcoma

    PharmaMar/J&J’ s Yondelis fast-tracked by FDA for sarcoma. Cancer drug could be approved in the US within months. ... We are particularly proud of this filing, as it represents our commitment to Yondelis and the people it may help," said Janssen's

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics